Wellington Management Group LLP increased its holdings in shares of Zenas BioPharma, Inc. (NASDAQ:ZBIO – Free Report) by 27.9% in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,593,819 shares of the company’s stock after purchasing an additional 347,766 shares during the quarter. Wellington Management Group LLP owned 2.45% of Zenas BioPharma worth $40,451,000 as of its most recent filing with the SEC.
Several other hedge funds have also recently bought and sold shares of ZBIO. BlackRock Inc. acquired a new position in shares of Zenas BioPharma in the second quarter valued at approximately $68,176,000. Bank of America Corp DE acquired a new stake in shares of Zenas BioPharma during the second quarter worth $31,247,000. Polar Capital Holdings Plc acquired a new stake in shares of Zenas BioPharma during the fourth quarter worth $38,402,000. Federated Hermes Inc. lifted its position in Zenas BioPharma by 45.9% in the 4th quarter. Federated Hermes Inc. now owns 2,715,578 shares of the company’s stock valued at $98,603,000 after acquiring an additional 853,740 shares in the last quarter. Finally, EcoR1 Capital LLC bought a new stake in Zenas BioPharma in the 4th quarter valued at $28,667,000.
Zenas BioPharma Stock Down 0.1%
Shares of ZBIO stock opened at $32.88 on Friday. The company has a current ratio of 9.93, a quick ratio of 9.93 and a debt-to-equity ratio of 1.57. Zenas BioPharma, Inc. has a 1 year low of $13.50 and a 1 year high of $44.60. The firm’s fifty day moving average price is $30.61 and its two-hundred day moving average price is $24.51. The firm has a market capitalization of $2.14 billion, a P/E ratio of -3.66 and a beta of -1.04.
Analysts Set New Price Targets
A number of equities analysts have issued reports on ZBIO shares. Weiss Ratings cut Zenas BioPharma from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, July 9th. Guggenheim reaffirmed a “buy” rating and set a $55.00 price objective on shares of Zenas BioPharma in a research report on Friday, August 14th. Zacks Research upgraded Zenas BioPharma from a “strong sell” rating to a “hold” rating in a report on Friday, May 15th. Wedbush reissued an “outperform” rating and issued a $45.00 target price on shares of Zenas BioPharma in a research report on Friday, August 14th. Finally, Morgan Stanley boosted their target price on Zenas BioPharma from $22.00 to $32.00 and gave the company an “equal weight” rating in a research note on Friday, August 14th. Six equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $45.71.
View Our Latest Research Report on Zenas BioPharma
Zenas BioPharma Profile
Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.
Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.
Recommended Stories
- Five stocks we like better than Zenas BioPharma
- Revolution Medicines Got Its Breakthrough—What Moves It Next?
- Retail Earnings Just Exposed a Bigger Divide in the U.S. Consumer Economy
- FB Financial’s Southern Expansion and Buybacks Drive Analyst Optimism
- AST SpaceMobile Stock Soared 12%—This Was the Catalyst
Want to see what other hedge funds are holding ZBIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zenas BioPharma, Inc. (NASDAQ:ZBIO – Free Report).
Receive News & Ratings for Zenas BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zenas BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
